Media headlines about EXACT Sciences (NASDAQ:EXAS) have been trending very positive on Saturday, according to AlphaOne Sentiment. The research firm, a subsidiary of Accern, identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real-time. AlphaOne ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. EXACT Sciences earned a media sentiment score of 0.50 on AlphaOne’s scale. AlphaOne also gave media coverage about the medical research company an impact score of 55 out of 100, meaning that recent news coverage is somewhat likely to have an effect on the company’s share price in the near term.
Here are some of the media stories that may have effected AlphaOne Sentiment’s analysis:
A number of brokerages recently commented on EXAS. Cowen and Company restated an “outperform” rating and issued a $45.00 price objective (up previously from $40.00) on shares of EXACT Sciences in a research report on Friday. Vetr downgraded shares of EXACT Sciences from a “strong-buy” rating to a “sell” rating and set a $28.55 price objective for the company. in a research report on Thursday, April 27th. Leerink Swann set a $38.00 price objective on shares of EXACT Sciences and gave the company a “buy” rating in a research report on Friday, April 28th. Goldman Sachs Group Inc set a $33.00 price objective on shares of EXACT Sciences and gave the company a “neutral” rating in a research report on Monday, May 1st. Finally, Zacks Investment Research downgraded shares of EXACT Sciences from a “hold” rating to a “sell” rating in a research report on Tuesday, April 25th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and eleven have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $26.24.
EXACT Sciences (NASDAQ:EXAS) traded up 10.86% during midday trading on Friday, reaching $35.43. 7,450,901 shares of the company traded hands. The firm has a 50 day moving average of $24.60 and a 200-day moving average of $19.25. EXACT Sciences has a 12 month low of $5.36 and a 12 month high of $35.83. The stock’s market capitalization is $3.92 billion.
EXACT Sciences (NASDAQ:EXAS) last released its quarterly earnings data on Thursday, April 27th. The medical research company reported ($0.32) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.41) by $0.09. EXACT Sciences had a negative net margin of 216.45% and a negative return on equity of 55.44%. The firm earned $48.36 million during the quarter, compared to analysts’ expectations of $37.38 million. During the same period in the previous year, the business posted ($0.49) earnings per share. The company’s revenue for the quarter was up 225.9% compared to the same quarter last year. Analysts forecast that EXACT Sciences will post ($1.36) EPS for the current fiscal year.
In other EXACT Sciences news, SVP D Scott Coward sold 7,046 shares of EXACT Sciences stock in a transaction on Monday, February 27th. The shares were sold at an average price of $21.48, for a total transaction of $151,348.08. Following the completion of the transaction, the senior vice president now directly owns 53,794 shares of the company’s stock, valued at $1,155,495.12. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Graham Peter Lidgard sold 8,668 shares of EXACT Sciences stock in a transaction on Monday, February 27th. The stock was sold at an average price of $21.51, for a total transaction of $186,448.68. Following the transaction, the insider now directly owns 314,527 shares of the company’s stock, valued at $6,765,475.77. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 47,987 shares of company stock valued at $1,028,453. Company insiders own 5.60% of the company’s stock.
EXACT Sciences Company Profile
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.